Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma

Recruiting now · Phase 2

Conditions studied: Osteosarcoma

In brief

To evaluate the clinical application value in bone marrow protection of Trilaciclib in the neoadjuvant treatment of stage II/III classic osteosarcoma in combination with pirarubicin and lobaplatin.

Key facts

Study ID

NCT06714383

Run by

Peking University People's Hospital

People needed

50

Starts

2024-11-13

Expected to finish

2025-11-01

Last updated by the study team

2024-12-03

Who can join

Age: 14 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Written informed consent signed;
• Classic osteosarcoma confirmed by histopathology (high grade);
• Newly diagnosed stage Ⅱ-Ⅲ based on Enneking staging criteria;
• Planned to receive neoadjuvant chemotherapy;
• Measurable disease on CT by RECIST 1.1.
• No antitumor system therapy received;
• ECOG 0-1
• Adequate organ function.
• Females of childbearing potential as well as males and their partners must agree to use an effective form of contraception during the study and for 6 months following the last dose of study medication.

You may not qualify if…

• History of malignancies of other type;
• Allergic to study agent;
• History of psychotropic substance abuse, alcohol or drug use;
• The researchers considered inappropriate to join the study of any cause.

Where it is running

• Peking University People's Hospital — Beijing, Beijing Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.